Oncternal Therapeutics, a leading biopharmaceutical company, is set to release its first-quarter financial results on May 9, 2024, after the U.S. financial markets close. The company, listed on Nasdaq under the ticker symbol ONCT, specializes in developing innovative oncology therapies to address critical unmet medical needs in cancer treatment.
The management of Oncternal Therapeutics will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) on the same day to provide a comprehensive business update and discuss the financial results. The live webcast will be available on the company’s investor website and will be archived for at least 30 days for those who are unable to attend the event.
Oncternal Therapeutics focuses on developing novel therapies targeting biological pathways involved in cancer development and progression, with a particular emphasis on hematological malignancies and prostate cancer. One of their investigational drugs, ONCT-534, is a dual-action androgen receptor inhibitor showing promising preclinical activity in prostate cancer models.
Additionally, the company is working on ONCT-808, an autologous chimeric antigen receptor T (CAR T) cell therapy that targets Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1). This therapy has demonstrated activity in preclinical models against various hematological malignancies and solid tumors.
Oncternal Therapeutics is dedicated to advancing the field of oncology and providing innovative treatment options for patients with cancer. Investors and stakeholders are eagerly awaiting the upcoming financial results and business update to gain insights into the company’s progress and future prospects.